FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198803497> ?p ?o ?g. }

• W3198803497 abstract "Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors, has revolutionized the systematic treatment of advanced and metastatic solid tumors. However, the response rate to ICIs is unsatisfactory, and unexpected hyperprogressive disease (HPD) is even observed in a small subgroup of patients. Patients with HPD usually have worsening clinical symptoms and poorer survival, and therapeutic strategies are extremely limited. Here, we presented a patient with HPD who had used a PD-L1 inhibitor and was highly responsive to the sequential use of a PD-1 inhibitor. A 67-year-old woman with metastatic triple-negative breast cancer was treated with pembrolizumab plus chemotherapy after progression on previous multiple-line chemotherapy treatments. After 2 cycles of treatments, she rapidly developed HPD, as confirmed by radiological evaluation and worsening symptoms. At that time, pembrolizumab was discontinued, and she switched to the PD-L1 inhibitor atezolizumab plus chemotherapy. This patient partially responded to atezolizumab plus chemotherapy without experiencing severe drug-related adverse effects. This is the first reported case of metastatic breast cancer in a patient with radiologically confirmed HPD after pembrolizumab therapy in which successful rechallenge with atezolizumab relieved clinical symptoms. Further studies with larger sample sizes involving a deeper translational investigation of HPD are needed to confirm the efficacy and mechanism of sequential application of different ICIs for the clinical management of HPD." @default.
• W3198803497 created "2021-09-13" @default.
• W3198803497 creator A5038693469 @default.
• W3198803497 creator A5042241049 @default.
• W3198803497 creator A5042377034 @default.
• W3198803497 creator A5047493747 @default.
• W3198803497 creator A5053359122 @default.
• W3198803497 creator A5062522073 @default.
• W3198803497 creator A5063401461 @default.
• W3198803497 creator A5087471441 @default.
• W3198803497 creator A5089045982 @default.
• W3198803497 date "2021-05-31" @default.
• W3198803497 modified "2023-10-14" @default.
• W3198803497 title "Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature" @default.
• W3198803497 cites W2004630197 @default.
• W3198803497 cites W2096322385 @default.
• W3198803497 cites W2554618897 @default.
• W3198803497 cites W2601621622 @default.
• W3198803497 cites W2601854298 @default.
• W3198803497 cites W2605497049 @default.
• W3198803497 cites W2625684877 @default.
• W3198803497 cites W2725398806 @default.
• W3198803497 cites W2770082995 @default.
• W3198803497 cites W2799838772 @default.
• W3198803497 cites W2891266481 @default.
• W3198803497 cites W2891951654 @default.
• W3198803497 cites W2895006950 @default.
• W3198803497 cites W2897422388 @default.
• W3198803497 cites W2898126801 @default.
• W3198803497 cites W2898432308 @default.
• W3198803497 cites W2909349708 @default.
• W3198803497 cites W2909955819 @default.
• W3198803497 cites W2935797142 @default.
• W3198803497 cites W2941582519 @default.
• W3198803497 cites W2969414846 @default.
• W3198803497 cites W2979775428 @default.
• W3198803497 cites W2982611301 @default.
• W3198803497 cites W2982865941 @default.
• W3198803497 cites W2985694569 @default.
• W3198803497 cites W2987614176 @default.
• W3198803497 cites W2989703847 @default.
• W3198803497 cites W2990166261 @default.
• W3198803497 cites W2990863896 @default.
• W3198803497 cites W2991072394 @default.
• W3198803497 cites W2991361825 @default.
• W3198803497 cites W2996017211 @default.
• W3198803497 cites W3004453915 @default.
• W3198803497 cites W3004667306 @default.
• W3198803497 cites W3010976613 @default.
• W3198803497 cites W3011497962 @default.
• W3198803497 cites W3028423564 @default.
• W3198803497 cites W3045574498 @default.
• W3198803497 cites W3049075450 @default.
• W3198803497 cites W3087132119 @default.
• W3198803497 cites W3107112451 @default.
• W3198803497 cites W3109853980 @default.
• W3198803497 doi "https://doi.org/10.3389/fimmu.2021.608292" @default.
• W3198803497 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8201609" @default.
• W3198803497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34135884" @default.
• W3198803497 hasPublicationYear "2021" @default.
• W3198803497 type Work @default.
• W3198803497 sameAs 3198803497 @default.
• W3198803497 citedByCount "9" @default.
• W3198803497 countsByYear W31988034972022 @default.
• W3198803497 countsByYear W31988034972023 @default.
• W3198803497 crossrefType "journal-article" @default.
• W3198803497 hasAuthorship W3198803497A5038693469 @default.
• W3198803497 hasAuthorship W3198803497A5042241049 @default.
• W3198803497 hasAuthorship W3198803497A5042377034 @default.
• W3198803497 hasAuthorship W3198803497A5047493747 @default.
• W3198803497 hasAuthorship W3198803497A5053359122 @default.
• W3198803497 hasAuthorship W3198803497A5062522073 @default.
• W3198803497 hasAuthorship W3198803497A5063401461 @default.
• W3198803497 hasAuthorship W3198803497A5087471441 @default.
• W3198803497 hasAuthorship W3198803497A5089045982 @default.
• W3198803497 hasBestOaLocation W31988034971 @default.
• W3198803497 hasConcept C121608353 @default.
• W3198803497 hasConcept C126322002 @default.
• W3198803497 hasConcept C143998085 @default.
• W3198803497 hasConcept C197934379 @default.
• W3198803497 hasConcept C2775930923 @default.
• W3198803497 hasConcept C2775949291 @default.
• W3198803497 hasConcept C2776694085 @default.
• W3198803497 hasConcept C2777701055 @default.
• W3198803497 hasConcept C2780057760 @default.
• W3198803497 hasConcept C2780110267 @default.
• W3198803497 hasConcept C530470458 @default.
• W3198803497 hasConcept C71924100 @default.
• W3198803497 hasConceptScore W3198803497C121608353 @default.
• W3198803497 hasConceptScore W3198803497C126322002 @default.
• W3198803497 hasConceptScore W3198803497C143998085 @default.
• W3198803497 hasConceptScore W3198803497C197934379 @default.
• W3198803497 hasConceptScore W3198803497C2775930923 @default.
• W3198803497 hasConceptScore W3198803497C2775949291 @default.
• W3198803497 hasConceptScore W3198803497C2776694085 @default.
• W3198803497 hasConceptScore W3198803497C2777701055 @default.
• W3198803497 hasConceptScore W3198803497C2780057760 @default.
• W3198803497 hasConceptScore W3198803497C2780110267 @default.
• W3198803497 hasConceptScore W3198803497C530470458 @default.
• W3198803497 hasConceptScore W3198803497C71924100 @default.

• next